The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 1st 2024
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer
Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.
BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable
The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.
BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus
September 30th 2013Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.
In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen
The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.